Richard Kane

Richard Kane provides data-driven analysis and economic insights for clients across multiple sectors.

He applies his background in payment and delivery system reform, microsimulation modeling, and economic forecasting to help clients understand new policies and respond to emerging trends. Richard brings to Avalere in-depth experience advising high-level policymakers on risk-based payment models in Medicare, including Accountable Care Organizations and bundled payments, and in building models that illuminate key concerns for policymakers on a wide range of health policy issues.

Prior to joining Avalere, Richard was a senior health economist for the White House Office of Management and Budget, leading economic analysis and modeling across all areas of health policy. Prior to that, as a senior economist for the Bureau of Economic Analysis, U.S. Department of Commerce, he led research, developed methods, and oversaw implementation of projects to improve macroeconomic measures.

Richard has a MIPP from The Johns Hopkins University, an MA in economics from The George Washington University, and a BA from Washington College. He is a London School of Economics Hansard Scholar.

Authored Content

CMMI’s impact on Medicare spending has so far not reached earlier projections by the Congressional Budget Office, demonstrating the difficulty in projecting savings from new and unknown alternative payment models.

The Center for American Progress (CAP) commissioned Avalere to evaluate ‘Medicare Extra’ as a package of reform polices implemented and phased in over time across the US healthcare system.

New research from Avalere finds that capped funding policies could reduce federal funding to states, specifically for children, by $89B to $163B nationally for FY 2020–2029.

Avalere experts recently presented “A Comprehensive Analysis of Influenza Vaccine Uptake in Medicare” at the National Adult and Influenza Immunization Summit in Atlanta, GA.

A new Avalere analysis finds that oncology practices participating in the Oncology Care Model (OCM) treated patients with 2–3% higher Medicare costs per episode, on average, than OCM prediction model estimates during the first two performance periods.

Pressure to lower costs will increase for OCM providers as CMS pushes to 2-sided risk.

Ahead of the American Society of Clinical Oncology's annual meeting, Avalere experts discussed the latest trends in policy, reimbursement, and market access reshaping oncology care.

New research from Avalere finds that the provision of pneumococcal conjugate vaccines increased immediately after ACIP’s 2014 recommendation to add the vaccine to the routine immunization schedule for older adults.

New Avalere analysis finds that most seniors in Medicare would not see a reduction in their out-of-pocket costs as a result of the International Price Index Model.

Avalere analysis finds that most of the payment reductions from the proposed International Pricing Index Model for Part B drugs would affect oncologists, rheumatologists, and ophthalmologists.

New research from Avalere finds that Medicare patients with rheumatoid arthritis (RA) may face higher out-of-pocket costs under a proposal to move Medicare Part B drugs into Part D, absent additional policy change to lower cost sharing in the Part D program.